Christopher Flores, PhD appointed as President and Chief Research and Development Officer of Doloromics, Inc.

November 8, 2021

Dr. Chris Flores joins DoloromicsDoloromics has announced the appointment of Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programs, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators in support of these efforts.

“After an extensive and diverse experience in the Pharmaceutical and Consumer sectors of Johnson & Johnson, I’m both thrilled and privileged to commit the full measure of my expertise and passion in executing the core mission of Doloromics, to eradicate pain in patients who remain tragically underserved by current standards of care.” -- Chris Flores, PhD.

Dr. Flores will complement the Doloromics leadership team after a successful, 19-year career at Johnson & Johnson, where he held several executive positions, including Vice President of Neuroscience, La Jolla R&D Site Head, Pain Franchise Strategy Leader, Head of Pain Discovery and Global External Innovation Head of Discovery Sciences within Janssen Research & Development as well as Head of Emerging Science and Innovation Strategy for J&J Consumer Companies.

About Doloromics

Doloromics, Inc. is the leading novel pain therapeutics development company. A spin-out of the University of Texas at Dallas, Doloromics is currently based out of Menlo Park, CA. The goal of Doloromics is to use our proprietary drug discovery platform, DOLOReS, to analyze transcriptomic and genomic sequencing data from chronic pain patients to identify novel therapeutic targets for chronic pain and then discover and develop transformational analgesics directed at those targets. For more information about Doloromics, visit

Categories: Drug Discovery & Development, Corporate, Finance & Investor
Browse more news

Recent releases